![]() ![]() “We are thrilled that the Cambridge Centre for AI in Medicine is taking off. CCAIM is designed to break down the barriers between machine learning and medical science, to create a unique forum in which we can work together to truly understand the challenges, formalise the problems, and develop practical solutions that can be readily implemented in healthcare.” But to realise this potential requires true and deep cross-disciplinary understanding – a great challenge because we speak different languages. “Machine learning has the potential to truly revolutionise the delivery of healthcare, to the great benefit of patients, clinicians and the wider medical ecosystem. The CCAIM team already has deep research links with the NHS, and four of the centre’s members are NHS doctors. The centre’s research output and the implementation of its ML tools could be transformational not only for the pharmaceutical industry – including in clinical trials and drug discovery – but also for the clinical delivery of healthcare to patients. These multi-disciplinary experts from the University of Cambridge will work in close collaboration with scientists and leaders from AstraZeneca and GSK to identify critical challenges facing drug discovery and development that have the potential to be solved through cutting-edge academic research. CCAIM brings together a diverse coalition of leading Cambridge scientists and clinicians, with expertise in machine learning, engineering, mathematics, medicine, computer science, genetics, computational biology, biostatistics, clinical research, healthcare policy and more. Successfully bridging the gap between the disparate and complex fields of AI and medicine requires building from both sides simultaneously. The faculty also includes Dr Sarah Teichmann FMedSci FRS, Head of Cellular Genetics at the Wellcome Sanger Institute and founder and principal leader of the Human Cell Atlas international consortium. The centre’s Director is Professor Mihaela van der Schaar, a world leading researcher in machine learning (ML), and the Co-Director is researcher-clinician Professor Andres Floto (bios below). ![]() Its faculty of 10 University of Cambridge researchers – in addition to world-class PhD students, currently being recruited – have united to develop AI and machine learning (ML) technologies aiming to transform clinical trials, personalised medicine and biomedical discovery. This program will enable the best and brightest young minds in machine learning and bioscience to partner with leaders in industry and academia, wherever they may be in the world.ĬCAIM has been set up as a cutting-edge research group. For the 5-year duration, AstraZeneca and GSK will support five new PhD studentships per year. Today the University of Cambridge announces a five-year agreement with AstraZeneca and GSK to fund the Cambridge Centre for AI in Medicine (CCAIM). ![]()
0 Comments
Leave a Reply. |